Aerosol therapy is the approach utilized to administer medication directly into the lungs and its airways. It is primarily a suspension of the liquids of solids administered utilizing the medical device likewise inhaler. The medical device transforms the medication into the fine aerosol particles that can be inhaled or directly influenced into the airway and lungs. The most utilized inhalation medications are bronchodilators and corticosteroids. The major respiratory disorders that are presently cured utilizing aerosol therapy comprise: Asthma, COPD, Bronchiectasis, cystic fibrosis, pulmonary arterial hypertension, and infectious pulmonary syndromes. The novel macromolecular medications are taking aerosol therapy a step further and the therapy is being tested for non-respiratory diseases such as diabetes, analgesia, and thyroid as well.
According to the report analysis, ‘Aerosol Therapy Market: Current Analysis and Forecast (2021-2027)’ states that Merck, Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, Novartis, Teva Pharmaceuticals, Opko Health, Omron Healthcare, Medtronic, and GE Healthcare. Countless M&As along with partnerships have been undertaken by such players to boost their existence in dissimilar regions.
Based on product, the aerosol therapy market can be sectored into dry powder inhalers, metered dose inhalers and nebulizers. Such segments can then further be sub segmented into single dose inhalers and multi dose inhalers of dry powder inhalers; conventional pressurized inhalers and soft mist inhalers of metered dose inhalers; and jet nebulizers, ultrasonic wave nebulizers, and vibrating mesh nebulizers of nebulizers. The nebulizers sector had the greatest CAGR in the reviewed period on account of its ability of usage in all age groups. In the past few years countless types of nebulizers have been introduced. Jet nebulizers are most utilized in patients with pulmonary syndromes as they are bulky and perform only with a power source.
Based on end-user, the aerosol therapy market is sectored into hospitals, clinics, ambulatory surgical centres, and individuals. The most primary end-users are hospitals and individuals. The most primary end-users are hospitals and individuals. Every year there are around 800,000 hospitalizations for Chronic obstructive pulmonary disease (COPD) around the United States which is the third leading source of death in the country.
Not only has this, presently, metered dose inhaler majorly underwrites to the market and is projected to register the market over the forecast duration. As per the data, COPD is third leading cause of death and fifth leading cause of disability. Also, aspects such as increasing pollution, improper lifestyles are the aspects that propel the growth of the market.
North America is predicted to register the market. Asia Pacific (mostly China and India) market is projected to grow at a relatively fast rate over the review period. Additionally, the effect of pollution is probable to intensify around the globe along with industrialization of locations, and growing the number of vehicles. Therefore, in the near years, it is predicted that the market of aerosol therapy will increase around the globe more actively over the near future.
For More Information, refer to below link:-
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
Support@kenresearch.com
+91-9015378249